

1 Moderate-Intensity Exercise Versus High-Intensity Interval Training to Recover Walking
2 Post-Stroke: Protocol for a Randomized Controlled Trial

3
4 Allison Miller PT, DPT, NCS¹, Darcy S. Reisman PT, PhD^{1,2}, Sandra A. Billinger PT,
5 PhD³, Kari Dunning PT, PhD⁴, Sarah Doren BS⁴, Jaimie Ward MS³, Henry Wright PT,
6 DPT², Erin Wagner MS⁴, Daniel Carl PhD⁴, Myron Gerson MD⁵, Oluwole Awosika MD,
7 MS⁶, Jane Khoury PhD⁷, Brett Kissela MD⁶, Pierce Boyne PT, DPT, PhD, NCS⁴

8
9 ¹Department of Biomechanics and Movement Sciences Program, University of Delaware, Newark,
10 Delaware 19713

11 ²Department of Physical Therapy, University of Delaware, Newark, Delaware 19713

12 ³Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center,
13 Kansas City, Kansas

14 ⁴Department of Rehabilitation, Exercise and Nutrition Sciences, University of Cincinnati, Cincinnati, Ohio

15 ⁵Departments of Cardiology and Internal Medicine, University of Cincinnati, Cincinnati, Ohio

16 ⁶Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio

17 ⁷Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Department of
18 Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio

19

20 **Corresponding Author:** Pierce Boyne PT, DPT, PhD, NCS, University of Cincinnati, 3225 Eden Avenue,
21 Cincinnati, Ohio, PH: 513-558-7499, FAX: 513-558-7474, boynepe@ucmail.uc.edu

22

23 **ABSTRACT:**

24 **Background:** Stroke results in neurologic impairments and aerobic deconditioning that
25 contribute to limited walking capacity which is a major barrier post-stroke. Current
26 exercise recommendations and stroke rehabilitation guidelines recommend moderate-
27 intensity aerobic training post-stroke. Locomotor high-intensity interval training is a
28 promising new strategy that has shown significantly greater improvements in aerobic
29 fitness and motor performance than moderate-intensity aerobic training in other
30 populations. However, the relative benefits and risks of high-intensity interval training
31 and moderate-intensity aerobic training remain poorly understood following stroke. In
32 this study, we hypothesize that locomotor high-intensity interval training will result in
33 greater improvements in walking capacity than moderate-intensity aerobic training.

34 **Methods:** Using a single-blind, 3-site randomized controlled trial, 50 chronic (>6
35 months) stroke survivors are randomly assigned to complete 36 locomotor training
36 sessions of either high-intensity interval training or moderate-intensity aerobic training.
37 Main eligibility criteria are: age 40-80 years, single stroke for which the participant
38 received treatment (experienced 6 months to 5 years prior to consent), walking speed
39 ≤ 1.0 m/s, able to walk at least 3 minutes on the treadmill at ≥ 0.13 m/s (0.3 mph), stable
40 cardiovascular condition (American Heart Association class B), and the ability to walk
41 10 meters overground without continuous physical assistance. The primary outcome
42 (walking capacity) and secondary outcomes (self-selected and fast gait speed, aerobic
43 fitness and fatigue) are assessed prior to initiating training and after 4 weeks, 8 weeks,
44 and 12 weeks of training.

45 **Discussion:** This study will provide fundamental new knowledge to inform the selection
46 of intensity and duration dosing parameters for gait recovery and optimization of aerobic
47 training interventions in chronic stroke. Data needed to justify and design a subsequent
48 definitive trial will also be obtained. Thus, the results of this study will inform future
49 stroke rehabilitation guidelines on how to optimally improve walking capacity following
50 stroke.

51 **Trial Registration:** ClinicalTrials.gov Identifier: NCT03760016. First posted: November
52 30, 2018. <https://clinicaltrials.gov/ct2/show/NCT03760016>

53 **Keywords:** gait, rehabilitation, dose, locomotion, treadmill, overground, clinical trial,
54 aerobic

55

56

57

58

59

60

61

62

63

64

65 **BACKGROUND:**

66 ***Background and Rationale:***

67 Approximately 6.6 million Americans are currently living with chronic sequelae of
68 stroke of which a primary impairment is reduced walking capacity (1). Limited walking
69 capacity is a major barrier to recovery after stroke (2), and less than 10% of stroke
70 survivors have adequate walking speed and endurance to allow for normal daily
71 functioning, such as grocery shopping and occupational requirements (1, 3-6). Thus,
72 improving walking capacity is a primary goal of rehabilitation after stroke (2, 7).

73 To address impairments in walking capacity, current exercise recommendations
74 and stroke rehabilitation guidelines recommend moderate-intensity aerobic training
75 (MAT) (2, 8). Compared to conventional rehabilitation approaches and lower intensity
76 training, MAT has shown significant benefits across a range of outcomes, such as
77 improvements in aerobic fitness (9-11), walking capacity (10-14), and overall disability
78 (14). However, this approach has known limitations that has restricted its adoption in
79 most clinical stroke rehabilitation settings (2). In particular, MAT has shown small and
80 inconsistent effects on gait speed, a primary outcome of stroke rehabilitation (10, 11,
81 13). In addition, most laboratory-based MAT protocols have involved training durations
82 (typically 45 minutes, 3x/week for 6 months) (15-22) beyond what is possible in clinical
83 practice due to issues related to patient adherence (23-25) and reimbursement (26, 27).
84 Thus, to improve walking capacity post stroke, there is a critical need for a more
85 efficacious and time-efficient intervention.

86 Recent evidence suggests that a more vigorous training intensity (>60% vs. 40-
87 60% heart rate reserve) may be a ‘critical ingredient’ for greater and more rapid
88 improvements in walking capacity (28). However, the presence of neurologic gait
89 impairments in individuals post stroke can make it challenging to reach this vigorous
90 intensity (29, 30). Locomotor high-intensity interval training (HIT) is a promising new
91 strategy for stroke rehabilitation that uses bursts of maximum speed walking alternated
92 with recovery periods, which allows individuals to sustain higher aerobic intensities than
93 physiologically possible with continuous exercise (28). Adding treadmill HIT to inpatient
94 stroke rehabilitation has been shown to significantly improve gait outcomes (31, 32). A
95 preliminary study in chronic stroke demonstrated that treadmill HIT can elicit significant
96 increases in walking capacity, gait speed and aerobic fitness in just 4 weeks (33). A
97 subsequent report showed the feasibility of combining treadmill and overground HIT in
98 an effort to better translate treadmill gait improvements into the normal overground
99 walking environment (34). Thus, HIT serves as a promising new strategy to target
100 impairments in aerobic fitness and motor impairment through its ability to achieve higher
101 aerobic intensities and demonstrate improvements in walking capacity in shorter training
102 durations.

103 Despite promising preliminary evidence, no previous studies have compared HIT
104 with the current model recommended by stroke rehabilitation guidelines (MAT). In
105 addition, the optimal training duration dose for HIT remains unknown. The present study
106 intends to fill these gaps through completion of the following objectives: 1) Determine
107 the optimal locomotor training intensity for eliciting immediate improvements in walking
108 capacity among chronic stroke survivors, 2) Determine the minimum locomotor training

109 duration required to maximize immediate improvements in walking capacity in chronic
110 stroke, and 3) Understand the feasibility of implementing HIT at multiple sites across the
111 United States. The primary study hypothesis is that 4 weeks of HIT will elicit significantly
112 greater improvement in walking capacity compared to 4 weeks of MAT. Based on data
113 from a different gait intervention in a similar population (35), we also hypothesize that
114 compared with 4 and 8 weeks of HIT, 12 weeks of HIT will elicit significantly greater
115 improvements in walking capacity and increased benefit over MAT.

116 ***Trial Design:*** This is a single-blind, 3-site randomized controlled trial in which
117 participants are randomly assigned to one of two groups: locomotor moderate-intensity
118 aerobic training (MAT) or locomotor high-intensity interval training (HIT). Prior to
119 randomization, participants undergo a screening assessment and pre-training (PRE)
120 blinded outcome testing to determine eligibility. Once deemed eligible, participants
121 begin the intervention period of the study. The goal of the intervention period is to
122 complete 36 training sessions within 12 weeks, with up to one additional week for
123 makeup sessions in each 4-week training block. The intervention period consists of
124 three intervention blocks separated by repeated outcome testing after 4 weeks, 8 weeks
125 and 12 weeks of training (see Figure 1). Outcome testing is conducted by a blinded
126 physical therapist at each time point. The primary outcome for this study is walking
127 capacity (6-Minute Walk Test, (6MWT)), and the secondary outcomes are comfortable
128 and fastest gait speed (10-Meter Walk Test, (10MWT)), aerobic fitness (VO₂ at
129 ventilatory threshold), and PROMIS Fatigue Scale total score. Exploratory measures
130 are scores on the Activities-Specific Balance Confidence Scale, EuroQOL-5D-5L,
131 Functional Ambulation Category, participant ratings of change, daily walking activity,

132 spatiotemporal measures of comfortable speed instrumented walkway gait testing,
133 resting heart rate and blood pressure, body mass index, metabolic cost of gait during
134 treadmill exercise testing, heart rate cost of gait during 6MWT (average heart rate
135 divided by average speed in meters/minute), difference in gait speed from the beginning
136 to end of the 6MWT, and other measures of aerobic fitness (e.g. VO_2 peak).

137

138 **METHODS: PARTICIPANTS, OUTCOMES, INTERVENTIONS**

139 **Study Setting:** This is a multisite clinical trial in which participants are recruited at three
140 sites: University of Cincinnati (UC), University of Delaware (UD), and University of
141 Kansas Medical Center (KUMC).

142 **Study Enrollment:** The target enrollment for this study is a total of 50 participants over
143 3 years (approximately 6 enrolled participants per site per year). As we anticipate a
144 screen failure rate of up to 40%, we expect to consent up to 70 participants
145 (approximately 8 consented participants per site per year) to meet the target enrollment.

146 **Recruitment:** Recruitment will utilize multiple approaches, including: 1) Continuous
147 outreach to regional therapists and physicians, 2) Outreach to stroke support groups, 3)
148 Advertisements in newspapers, magazines, social media, physician offices and/or
149 therapy clinics, 4) Leveraging existing databases of local stroke survivors interested in
150 participating in research, 5) Screening medical records for potentially eligible
151 participants (UC and KUMC sites only).

152 **Screening Process:** A member of the study team provides an overview of the study
153 and determines initial interest in participation either in-person or via phone. The

154 potential risks and benefits of participation are described. Potential participants are
155 informed that participating in the study is completely voluntary and that he/she may
156 discontinue participation at any time. For individuals who express interest, the study
157 team member asks pre-screening questions to determine initial eligibility and answer
158 any participant questions. For individuals who meet criteria according to pre-screening
159 questions, a screening visit is scheduled. Each study site maintains a log to document
160 the potential number of participants (or caregivers) contacted.

161 **Informed Consent:** A study team member describes the study procedures and
162 potential risks and benefits in detail at the start of the screening visit. Prior to signing
163 informing consent, participants are asked standardized questions to ensure that the
164 individual understands the study before consenting.

165 **Eligibility Criteria:** The inclusion criteria for this study are as follows: 1) Age 40-80
166 years at the time of consent, 2) Single stroke for which the participant sought treatment,
167 6 months to 5 years prior to consent, 3) Walking speed ≤ 1.0 m/s on the 10-meter walk
168 test, 4) Able to walk 10m over ground with assistive devices as needed and no
169 continuous physical assistance from another person, 5) Able to walk at least 3 minutes
170 on the treadmill at ≥ 0.13 m/s (0.3 mph), 6) Stable cardiovascular condition (American
171 Heart Association class B, allowing for aerobic capacity <6 METs), 7) Able to
172 communicate with investigators, follow a 2-step command and correctly answer consent
173 comprehension questions.

174 Exclusion criteria for this study are: 1) Exercise testing uninterpretable for
175 ischemia or arrhythmia, 2) Evidence of significant arrhythmia or myocardial ischemia on
176 treadmill ECG graded exercise test in the absence of recent (past year) more definitive

177 clinical testing with negative result, 3) Hospitalization for cardiac or pulmonary disease
178 within the past 3 months, 4) Implanted pacemaker or defibrillator, 5) Significant ataxia or
179 neglect (score of 2 on NIH stroke scale item 7 or 11), 6) Severe lower limb spasticity
180 (Ashworth >2), 7) Recent history (<3 months) of illicit drug or alcohol abuse or
181 significant mental illness, 8) Major post-stroke depression (Patient Health Questionnaire
182 (PHQ-9) ≥ 10) in the absence of depression management by a health care provider, 9)
183 Currently participating in physical therapy or another interventional study, 10) Recent
184 botulinum toxin injection to the paretic lower limb (<3 months) or planning to have lower
185 limb botulinum toxin injection in the next 4 months, 11) Foot drop or lower limb joint
186 instability without adequate stabilizing device, as assessed by a physical therapist, 12)
187 Clinically significant neurologic disorder other than stroke or unable to walk outside the
188 home prior to stroke, 13) Other significant medical condition likely to limit improvement
189 or jeopardize safety as assessed by a physical therapist, 14) Pregnancy, 15) Previous
190 exposure to fast treadmill walking (>3 cumulative hours) during clinical or research
191 therapy in the past year.

192 ***Participant Timeline:*** After obtaining informed consent, participants undergo a
193 Screening Visit to determine preliminary eligibility and record some clinical
194 characteristics. If the participant is potentially eligible after completing the Screening
195 Visit, the participant then performs a PRE testing visit with a blinded testing therapist to
196 complete the eligibility assessment and obtain baseline data for the outcome measures.
197 In total, there are four evaluation periods throughout study participation. Participants
198 undergo evaluation assessments by a blinded testing therapist before starting the
199 intervention period (PRE), after 4 weeks of training (4-WK), after 8 weeks of training (8-

200 WK), and after completing 12 weeks of training (POST), see Figure 1. The evaluation
201 procedures occurring at each of these four time points are the same and include the
202 following measures: 6-Minute Walk Test, comfortable and fastest gait speed testing,
203 treadmill graded exercise testing (GXT), questionnaires and recording of daily stepping
204 activity. In addition, at the 4-WK, 8-WK, and POST evaluation time points, a global
205 rating of change questionnaire is included that inquires about perceived changes in the
206 participant's walking abilities and fatigue levels as they progress through the study
207 protocol.

208 **Screening Visit Eligibility Measures:** During the Screening Visit, a study team
209 member obtains the participant's medical history, screens for the presence of
210 depressive symptoms, performs impairment and mobility assessments of the
211 participant, and performs StepWatch calibration procedures to begin step activity
212 monitoring. Medical history information includes characteristics of the participant's
213 stroke, comorbidities, medications, surgical history, previous therapies, pain, and
214 mobility status prior to their stroke. Additionally, the study team member instructs the
215 participant to complete the Patient Health Questionnaire-9 to screen for depressive
216 symptoms (36). Assistance is provided to the participant by the study team member if
217 needed to complete the questionnaire.

218 The physical assessment portion of the Screening Visit consists of impairment
219 testing and mobility assessments. During impairment testing, the following measures
220 are administered:

- 221 • **Two-step command following:** The participant is asked to “close your eyes and
222 make a fist”. If the individual is unable to follow two-step commands, they are
223 ineligible for this study.
- 224 • **Lower extremity Fugl-Meyer (LEFM):** The LEFM is a stroke-specific measure of
225 lower extremity motor impairment and includes an assessment of the participant’s
226 reflexes and their ability to perform movements requiring different amounts of
227 fractionated control (37). It will be used to characterize the study sample.
- 228 • **Ashworth Hypertonia Assessment:** This includes an assessment of the
229 participant’s passive resistance to joint movement at their paretic lower extremity
230 (38). The Ashworth Scale is scored as “excessive” (Ashworth ≥ 3) or “acceptable”
231 (Ashworth <3). Individuals with Ashworth scores of ≥ 3 at their paretic lower
232 extremity are ineligible for this study.
- 233 • **Ataxia and neglect testing:** Two items from the National Institutes of Health Stroke
234 Scale (NIHSS) are used to screen for severe ataxia or neglect to determine
235 participant eligibility (39). An assessment of upper and lower extremity coordination
236 is used to determine the presence or absence of limb ataxia. Participants with ataxia
237 in more than one out of four limbs (i.e. ataxia score of 2) are ineligible for study
238 participation. Neglect testing includes an assessment of extinction to bilateral
239 simultaneous visual and tactile stimulation. Participants who present with extinction
240 to both sensory modalities or demonstrate behavioral evidence of profound hemi-
241 inattention (i.e. extinction score of 2) are ineligible for study participation.

242 The mobility assessment of the Screening Visit consists of the following:

- 243 • **Walking-related pain assessment:** A study team member queries the participant
244 about any pain related to walking. If the participant's walking is limited by pain, the
245 participant is asked further questions related to how the pain changes during
246 walking. Based on the severity and characteristics of the participant's pain, this may
247 exclude them from study participation if it is determined that pain is likely to limit
248 improvement or jeopardize safety.
- 249 • **Comfortable and fast gait speed measurements:** The 10MWT is used to assess
250 the participant's comfortable and fastest gait speeds. An untimed 2-meter
251 acceleration distance is provided, followed by 10 meters of timed walking, and a 2-
252 meter untimed deceleration distance. Participants are asked to use the assistive and
253 orthotic devices that they most often use when walking. During the Screening Visit,
254 comfortable gait speed is averaged over two trials. Participants whose average gait
255 speed is greater than 1.0 m/s are excluded from study participation. If eligibility
256 criteria are met at comfortable gait speed, a 10MWT at the participant's fastest gait
257 speed is performed. The 10MWT is a valid and reliable measure of walking speed in
258 individuals post stroke (40).
- 259 • **Height and weight assessment:** The participant's height and weight are obtained
260 at the Screening Visit. Weight is reassessed at the 4-WK, 8-WK, and POST time
261 points and used to normalize metabolic data from GXT testing at these time points.
- 262 • **Treadmill acclimation and screening assessment:** This assessment is used to
263 determine eligibility and for preparation for exercise testing. As this study involves
264 considerable treadmill walking, the treadmill acclimation provides the participant with
265 the opportunity to acclimate to the treadmill and provides the study team with an

266 idea of how fast the participant can safely walk on the treadmill. During treadmill
267 walking, the participant's heart rate (HR) is monitored using a Polar heart rate
268 monitor synched to the Digifit iCardio app to provide real-time HR monitoring. The
269 study team member administering the test ensures that the participant's HR does
270 not exceed 80% age-predicted heart rate reserve (HRR) during this test. The
271 participant wears a harness that is attached to an overhead system for protection in
272 the event of a fall and is asked to hold onto the handrail during testing. The treadmill
273 is started at a slow speed and gradually increased in communication with the
274 participant. The speed goal for this test is the participant's fast overground speed or
275 0.3 mph, whichever is higher. Rest breaks are provided to maintain <80% HRR, and
276 a post-exercise blood pressure is taken upon completing the test. Participants must
277 be able to walk at least 0.3 mph on the treadmill to be eligible for study participation.

278
279 After the Screening Visit (but before the PRE evaluation visit), pertinent medical
280 records are obtained to ensure the participant is safe to participate in the study. A
281 radiology report confirming stroke and its location is also obtained. Participants who do
282 not meet one or more of the eligibility criteria that can be assessed from the Screening
283 Visit are excluded (see Eligibility Criteria above).

284
285 **Step Activity Monitoring:** For participants that meet eligibility criteria at the time of the
286 Screening Visit, a step activity monitor (Modus StepWatch) is calibrated and issued to
287 the participant to wear throughout the study protocol during all waking hours except
288 bathing. The StepWatch is calibrated per the manufacturer's instructions and synced to

289 an iPad app that enables study team members to download the participant's stepping
290 activity throughout the study protocol. At the start of each subsequent study visit, a
291 study team member "reads" the step activity data and records the stepping activity and
292 respective dates in the study's electronic data management system, REDCap
293 (Research Electronic Data Capture). Stepping activity data is also recorded at the end
294 of each study visit which enables study team members to discern steps taken within
295 each study session from steps taken outside of study visits. While reading step activity
296 data, the study team member checks for data irregularities (e.g. missing steps in the
297 first or last half of non-study-visit days) and queries the participant to determine if a
298 particular day should be deemed a valid recording day. If it is likely that >10% of walking
299 bouts that day were not recorded, then it is documented as not a valid recording day.

300 **Outcomes:** The following measures are assessed at the PRE, 4-WK, 8-WK, and POST
301 evaluation time points and are conducted by a licensed physical therapist who is blinded
302 to group randomization. The goal is to complete all of the tests in the same visit and
303 within 2-7 days since the last training session in the preceding intervention block.

304 Whenever possible, gait testing (i.e. 6MWT and 10MWT) is completed prior to graded
305 exercise testing, as gait testing includes the primary outcome measure. Blood pressure
306 and HR are taken at each visit. For all questionnaires, the participant is encouraged to
307 self-administer (if able) to reduce any influence that the study team member may have
308 on their responses.

- 309 • **6-Minute Walk Test (6MWT):** The 6MWT is a measure of walking capacity and is
310 the primary outcome measure for this study. Study team members ensure that the
311 participant is provided with adequate rest prior to performing this measure.

312 Participants are instructed to walk as far and fast as they can for six minutes and are
313 asked to use the orthotic and assistive devices they most often use during normal
314 daily walking (41). Participants walk along a marked pathway that was required to be
315 at least 20 meters long at each site. At UC and KUMC, participants walk back and
316 forth between two cones spaced 25 meters apart. At UD, participants walk around a
317 rectangular course with a 103.6-meter perimeter. The participant is informed that
318 they may stop and rest as needed but that the timer will keep counting down.
319 Participants are notified how much time has elapsed in 1-minute intervals, and HR is
320 monitored and continuously recorded throughout the test. The total distance walked,
321 time to walk the first 25-meter length or 100 feet, time to walk the last complete 25-
322 meter length or 100 feet, average HR, and max HR are recorded in REDCap. The
323 6MWT is a valid and reliable measure of walking endurance in individuals post
324 stroke (40, 42).

- 325 • **Comfortable and Fast 10-meter Walk Test:** The participant's comfortable and fast
326 gait speeds are assessed using the 10MWT in the same manner as described
327 above. Two comfortable speed trials and two fast speed trials are taken at each of
328 the four outcome testing time points.
- 329 • **Treadmill Exercise Testing with Metabolic Cart:** At each evaluation time point
330 during the study, a treadmill graded exercise test (GXT) is performed. Exercise
331 testing is performed on a motorized treadmill with a 12-lead electrocardiogram
332 (ECG) and metabolic cart for analysis of VO_2 . At the start of the test, the participant's
333 resting vital signs and ECG are obtained. Participants then walk on a treadmill
334 wearing a harness attached to an overhead system for fall protection and hold onto

335 the treadmill handrail. The starting treadmill speed is 0.3 mph for the first 3 minutes
336 and then gradually increases in increments of 0.1 mph every 30 seconds until peak
337 volitional exertion. The incline of the treadmill remains 0% unless the participant
338 achieves a speed of 3.5 mph at which time the incline increases in increments of
339 0.5% every 30 seconds while the speed remains fixed. Ratings of perceived exertion
340 (RPE) (43) and blood pressure are assessed every two minutes during the test. Test
341 termination criteria include the participant's request to stop, the participant drifting
342 backward on the treadmill and being unable to recover, gait instability judged to pose
343 an imminent safety risk by the testing therapist, and other stop criteria according to
344 American College of Sports Medicine guidelines (44). After completion of this test
345 and a 10-minute rest period, participants are asked to attempt a 3-minute verification
346 test to determine whether maximum heart rate was reached. During the verification
347 test, the speed is increased to the last successfully completed stage from the GXT,
348 and a 3-minute timer is started once the treadmill has reached this target stage.
349 Participants are encouraged to try and complete the full 3 minutes of the verification
350 test when possible. VO_2 is not measured during the verification test. Guidelines for
351 stopping criteria are the same as the GXT, except that the verification phase can be
352 stopped once the participants completes the 3 minutes. The instantaneous peak HR
353 from the verification test is recorded in the study's electronic database. During the
354 PRE period, a physician or medical monitor reviews the test results to ensure safety
355 to continue with the study protocol. In this study, the peak heart rate achieved during
356 the GXT or verification test (whichever is higher) is used to derive training intensity
357 zones. If the participant does not achieve 85% of their age-predicted maximum heart

358 rate during the GXT or verification test (44), the peak GXT or verification test heart
359 rate (whichever is higher) is also used as a heart rate limit during subsequent
360 training sessions. VO_2 at the ventilatory threshold is a secondary outcome for this
361 study as evidence suggests that this measure may be a more valid assessment of
362 aerobic capacity compared to VO_2 peak in individuals with stroke (45).

- 363 • **PROMIS Fatigue Scale (Version 8a):** The PROMIS Fatigue Scale is an 8-item self-
364 report questionnaire that inquires about the participant's fatigue over the past seven
365 days (46). Responses are rated on a 5-point Likert scale from 'not at all' to 'very
366 much'.
- 367 • **Functional Ambulation Category (FAC):** The FAC is a measure of walking
368 independence and is scored on a scale of 0-5 (47). A member of the study team
369 rates the participant's level of walking independence based on their walking
370 performance during the 10MWT and 6MWT. For this study, only scores of 2-4 are
371 permitted as individuals obtaining lower scores would not meet the eligibility criteria,
372 and a score of 5 would require observation of the participant walking on different
373 types of non-level surfaces, which is not part of this study.
- 374 • **EQ-5D Quality of Life Questionnaire (Version 5L):** The EQ-5D is a 6-item
375 questionnaire about quality of life as it relates to mobility, self-care, usual activities,
376 pain/discomfort, anxiety/depression, and overall health (48).
- 377 • **Activities Specific Balance Confidence Scale (ABC):** The ABC is a 16-item
378 questionnaire that asks participants to rate their balance confidence during everyday
379 tasks on a scale from 0% to 100% (49). Scores are averaged to provide an overall
380 value representing the participant's perceived balance confidence.

- 381 • **Global Rating of Change (GROC):** This questionnaire asks participants to rate their
382 perceived change in areas related to their walking abilities and walking habits since
383 beginning the study (not applicable at PRE testing) (50). Responses are scored on a
384 7-point ordinal scale ranging from ‘much better’ to ‘much worse’.
- 385 • **Electronic Walkway Gait Assessment:** Before starting the first training session in
386 each intervention block (i.e. training sessions 1, 13, and 25) and the final training
387 session (i.e. session 36), the participant’s comfortable speed gait parameters are
388 recorded with two passes across an electronic walkway (e.g. GaitRITE). Participants
389 are asked to use their habitual assistive and orthotic devices. The following gait
390 parameters are recorded in REDCap: gait velocity, cadence, right and left step
391 lengths (cm), right and left step times (s), right and left single limb support (% of gait
392 cycle), and right and left stride velocity (cm/s).

393 **Allocation:** Eligible participants are randomized after the PRE blinded outcome testing
394 visit and before the first training session. Participants are randomized in a 1:1 ratio to
395 either HIT or MAT, using the REDCap randomization module. This module ensures
396 concealed allocation by requiring the study team member to confirm participant eligibility
397 prior to revealing the randomization allocation and not permitting anyone to un-
398 randomize a participant. The study statistician who computer-generated the
399 randomization sequence and uploaded it to REDCap is the only person who has access
400 to view it and has no interaction with study participants (e.g. not involved with
401 recruitment or enrollment). Randomization is stratified by site and baseline walking
402 speed (<0.4 , ≥ 0.4 m/s) to help ensure that groups are balanced within sites and on this
403 critical prognostic factor (51, 52). Within each stratum, block size is randomly permuted

404 to prevent study personnel from being able to predict the last randomization within a
405 block. SAS® (SAS Institute, Cary, NC) PROC PLAN was used to create the
406 randomization scheme.

407 **Interventions:** Participants are randomly assigned to either MAT or HIT. Study
408 interventions are administered under the direction of a licensed physical therapist. For
409 each intervention block, the goal is to complete 12 training sessions within 4 weeks,
410 with an additional week allowed for makeup sessions. The target frequency of training is
411 3 sessions per week (with one day of rest between training sessions, when possible).

412 The following procedures are common to both intervention groups. Each training
413 visit involves 45 minutes of exercise that consists of a 3-minute warm-up of overground
414 walking, 10 minutes of overground training, 20 minutes of treadmill training, 10 minutes
415 of overground training, and a 2-minute cool-down of overground walking. Throughout
416 training, participants use their customary orthotic devices. During overground training,
417 participants use the assistive device that best enables achievement of intervention
418 goals (fastest speed for HIT; target HR for MAT). The participant's overground gait
419 training speed is measured at the beginning and end of each overground bout. During
420 treadmill walking, participants wear a harness connected to an overhead support
421 system for fall protection and are asked to use a handrail for balance support. Guarding
422 is provided by the training therapist to help prevent falls or injury. No assistance or
423 cueing is provided to improve the participant's gait pattern.

424 During training, participants wear a heart rate monitor and step activity monitor to
425 monitor heart rate and stepping activity, respectively. Heart rate is monitored using the
426 Polar H7 Bluetooth 4.0 transmitter synced to an Apple iPod application (Digifit iCardio)

427 to enable continuous HR monitoring throughout the training session. The iPod
428 application is also used to time the duration of each component of training (e.g. 20-
429 minute treadmill bout). The target HR for training sessions is based on the participant's
430 highest HR achieved during the GXT or verification test. Resting HR values are
431 obtained at the start of the training visit in a standing position. Stepping activity data is
432 recorded before and after each treatment session to monitor steps taken during the
433 session.

434 Rating of Perceived Exertion (RPE), blood pressure, and blood lactate are also
435 monitored throughout the intervention protocol. Participants are shown an RPE chart at
436 the end of each training session and asked how hard they were working during the
437 session on average. Blood pressure is monitored at least once per session until a
438 consistent response within safety limits is established. Blood lactate concentrations are
439 measured in the middle session of each training week (i.e. every 3 training sessions
440 starting at session 2) immediately after completing the treadmill training portion of the
441 session. Immediately after treadmill training, the participant is instructed to sit on a chair
442 on the treadmill, and the training therapist obtains a measure of blood lactate via
443 fingerstick with caution taken to avoid sweat contamination and alterations in lactate
444 concentration due to vigorous finger squeezing.

445 If any of the following occur during a training session, exercise is paused (timer
446 will continue) and the training therapist decides whether early termination and/or
447 physician notification is warranted: 1) New onset pain, 2) HR consistently exceeding
448 peak HR achieved on most recent GXT or verification test (only if the participant has not
449 reached 85% age-predicted maximum heart rate during exercise test), 3) Difficulty

450 monitoring heart rate or blood pressure, 4) Participant requests a break. If any of the
451 following occur during a training session, the session is terminated, the participant's
452 physician is notified, and the site primary investigator decides whether to withdraw the
453 participant from the study: 1) Signs of poor perfusion, 2) Drop in systolic blood pressure
454 ≥ 10 mmHg below the resting level from that day despite an increase in workload, 3)
455 Hypertensive response with systolic blood pressure >240 mmHg and diastolic blood
456 pressure >110 mmHg, 4) New onset of significant nervous system symptoms or
457 claudication pain, 5) Chest pain or angina, 6) Severe fatigue or shortness of breath in
458 excess of what would be expected from exercise, 7) Serious injury.

459 **Locomotor moderate-intensity aerobic training (MAT).** Individuals
460 randomized to the MAT group perform continuous walking on the treadmill and
461 overground. During training, speed is continuously adjusted to maintain the following
462 target HR ranges: Training Sessions 1-6: $40 \pm 5\%$ HRR; Training Sessions 7-12: $45 \pm$
463 5% HRR, Training Sessions 13-18: $50 \pm 5\%$ HRR; Training Sessions 19-36: $55 \pm 5\%$
464 HRR. All attempts are made to keep heart rates below 60% HRR during MAT training
465 sessions as this is generally considered the threshold for vigorous intensity (44). During
466 overground MAT, the participant is instructed to walk continuously for 10 minutes, and
467 the training therapist instructs the participant to speed up or slow down to maintain their
468 heart rate in the desired training zone.

469 For treadmill MAT, participants walk continuously for 20 minutes if possible. At
470 the start of each session, the training therapist selects a speed that brings the
471 participant as close as possible to, but not exceeding, the target HR. For the first
472 training session, treadmill speeds start at $\sim 75\%$ of the participant's comfortable gait

473 speed from the most recent 10MWT. The training therapist then adjusts the speed as
474 needed to keep the participant's HR in the target zone. The training therapist decreases
475 the speed if the participant requests a speed decrease, the participant drifts backward
476 and does not immediately recover, gait instability is observed and judged to pose an
477 immediate safety risk, toe drag that persists into mid-swing is observed, or there is
478 evidence of excessive joint instability with risk of harm.

479 **Locomotor high-intensity interval training (HIT).** Individuals randomized to the
480 HIT group perform repeated 30 second bursts of walking at their maximum safe speed,
481 alternated with 30-60 second rest periods. During overground HIT, burst speed is
482 increased using visual feedback about the distance covered during each burst and
483 encouragement to increase distance. During treadmill HIT, speed is systematically
484 increased throughout each training session based on performance criteria. Speed is the
485 primary intensity target for the HIT group, and HR is secondary after speed is
486 maximized. This is primarily because the 30 second bursts are not long enough for
487 heart rate to reach steady state, so it fluctuates between burst and recovery and trends
488 upward over the session (53, 54). The target average HR for each session is ~70%
489 HRR, with a range from 60% to 95% HRR. If the participant reached their target HR of
490 85% of their age-predicted maximum (not adjusted for beta-blockers) during the GXT
491 and had normal results, then no HR limit is enforced. However, if the participant did not
492 reach their target HR once during any previous GXTs, their training HR is limited to their
493 maximum HR achieved across all previous GXTs.

494 During overground HIT training, the participant is instructed to walk as fast as
495 they can for 30 seconds. A marker is placed at the participant's starting position as well

496 as their final position after the 30-second burst. For future bursts, participants are
497 encouraged to achieve at least the distance they covered during previous bursts and
498 further if they are able. Sixty seconds of rest is provided after the first three bursts and
499 then decreased to 30 seconds rest periods thereafter. However, the training therapist
500 may consider extending the rest periods if the participant needs to sit down during
501 recovery, if the distance covered during the previous bursts significantly decreases with
502 shorter rest periods, if the participant requests an extended rest break, or if the
503 participant exceeds their heart rate limit.

504 When selecting speeds for treadmill HIT during bursts, the goal is to quickly find
505 the participant's fastest safe challenge speed and increase this speed as able
506 throughout the burst. The challenge speed is defined as the speed at which the
507 participant can safely complete the burst but has some backward drift or gait instability
508 with recovery. During the first treadmill HIT session, treadmill speeds start at ~75% of
509 the participant's peak successful speed from their most recent GXT. To determine an
510 initial challenge speed during bursts, the training therapist waits 15 seconds to allow the
511 speed to ramp up and the participant to acclimate, and then increases the speed by 0.1
512 mph every 5 seconds. Once the challenge speed is found, specific criteria are used to
513 determine whether subsequent burst speeds will be increased, maintained, or
514 decreased. If a burst is performed safely with no gait instability or backward drift, the
515 speed is increased by 0.1 mph for the next burst. If the challenge speed criteria are met,
516 the speed is kept the same for the next burst. If a burst is not performed safely or must
517 be stopped early due to backward drift without recovery or unsafe gait instability, the
518 speed is decreased by 0.1 mph for the next burst. Similar to overground HIT, 60

519 seconds of rest are provided in between the first three bursts, followed by 30 second
520 rest periods between subsequent bursts and similar criteria are used during treadmill
521 HIT to determine if an extended rest period is required.

522 ***Personnel Training and Standardization:*** A systematic training and competency
523 assessment program for all study therapists and coordinators has been implemented to
524 maintain standardization of study procedures across sites. Study personnel cannot
525 perform an official study role until certified for that role. The site primary investigator (PI)
526 and site coordinator ensure that the study team member meets competency
527 requirements. Study personnel training procedures include the following: 1) Reading the
528 study manual of operating procedures (MOP), 2) Complete online personnel training
529 modules related to their study roles 3) Practice using the study's electronic data
530 management system, REDCap, 4) Practice using all equipment required for their study
531 roles. Trainees must show competency in all aspects of their role before certification.
532 Recertification is done as needed based on the discretion of the site PI. A delegation of
533 authority log is maintained at each site to delineate the job roles of study team
534 members. Communication between the site PIs is maintained through meetings,
535 conference calls, or emails as needed to maintain consistency in study procedures
536 across sites.

537

538 **METHODS: DATA MANAGEMENT AND ANALYSIS**

539 ***Data Management:*** This study uses both electronic and hard-copy data management
540 procedures. For electronic database management, the secure data platform REDCap is

541 used, and the majority of study data is directly entered into the REDCap database using
542 an iPad during each study visit. This database includes automated calculations, quality
543 control checks and prompts (e.g. notification if entered data indicate participant is not
544 eligible, calculation of intensity targets, notification of whether entered intensity data are
545 within target range, prompts to fill in any missing data or to double check any values
546 outside of the expected range). Each study team member is provided a secure login for
547 the University of Cincinnati REDCap portal through the UC regulatory coordinator and
548 provided data access rights based on their study role such that blinded personnel
549 cannot access randomization or intervention data.

550 This study also generates some electronic data outside of REDCap that could be
551 further processed to obtain additional variables of interest. Examples of such data
552 include metabolic cart files, electronic walkway files, and StepWatch activity files. These
553 data files are uploaded and stored in a secure OneDrive folder that is designated for
554 research data so that they can be processed centrally. To maximize data security, no
555 participant identifiable information is entered into these files or the software that creates
556 these files. In addition, hard-copy records containing information that could be used to
557 identify participants (e.g. consent forms, medical records) and any hard copy forms
558 containing study data (e.g. temporary backup paper forms in case of power, internet or
559 REDCap server downtime) are maintained in a locked storage unit inside a controlled-
560 access room throughout the study. Regulatory documents are maintained according to
561 institutional requirements and guidelines specific to each site.

562 **Sample Size:** This study is powered to detect the minimally clinically important
563 difference (MCID) of 20 meters in walking capacity (6MWT) change between groups

564 (55). The 6MWT change estimate for the MAT group was extrapolated from a 4-week
565 pilot study and resulted in a change estimate of 15 meters every 4 weeks (33). The
566 6MWT change estimate for the HIT group was calculated by adding the MCID to the
567 MAT group estimate (15+20=35 meters every 4 weeks). Variance and covariance
568 parameters were estimated by pooling data across two previous 4-week studies (n=20),
569 using the mean variance for each time point and the highest suggested exponential
570 decay rate (0.5) (56) for the repeated measures correlations to extrapolate parameters
571 for the 8-WK and POST time points. These calculations indicated a target sample size
572 of 40 (20/group) for 80% power. To account for up to 20% attrition, the target enrollment
573 is 50 participants.

574 **Statistical Methods:** SAS v9.4 will be used for data analysis, and the study statistician
575 will remain blinded to study group. Data related to baseline variables, intervention
576 fidelity and concurrent outside interventions will be compared between groups using t-
577 tests and X^2 . If a baseline prognostic factor is found to differ between groups, it will be
578 considered for inclusion as a covariate during hypothesis testing. The primary analysis
579 will follow intent-to-treat methods and any missing data will be handled with the
580 maximum likelihood method, assuming that patterns of missingness do not violate the
581 missing at random assumption (57). To test robustness of different ways to handle
582 missing data, sensitivity analyses will be used.

583 Hypothesis 1: To test our primary hypothesis that, compared with 4 weeks of
584 MAT, 4 weeks of HIT will elicit significantly greater improvement in the 6MWT distance,
585 a general linear model will be used. In this model, we will use fixed effects for group
586 (HIT, MAT), time (PRE, 4-WK, 8-WK, POST), [group x time], site (UC, KUMC, UD), [site

587 x time], baseline speed category (<0.4 , ≥ 0.4 m/s), and [baseline speed category x time]
588 with an unstructured covariance matrix. This hypothesis will be tested by the
589 significance of the [group x time] contrast from the PRE to 4-WK for the 6MWT at
590 $\alpha=0.05$. Secondary outcomes will be tested separately using this same model to identify
591 the most sensitive measures to carry forward into future studies (58). The Benjamini-
592 Hochberg procedure (59) will be used to control the false discovery rate for the
593 secondary outcomes.

594 Hypothesis 2: To test the hypothesis that, compared with 4 and 8 weeks of HIT,
595 12 weeks of HIT will elicit significantly greater improvements in walking capacity and
596 increased benefit over MAT, the same general linear model described above will be
597 used. The hypothesis that 12 weeks of HIT will elicit greater improvements in primary
598 and secondary outcomes compared to 4 and 8 weeks of HIT will be tested by the
599 significance of the respective time contrasts within the HIT group. The hypothesis that
600 HIT will elicit significantly greater improvements in primary and secondary outcomes
601 from PRE to 8-WK and PRE to POST compared to MAT will be tested by the
602 significance of the respective [group x time] contrasts. False discovery rate control will
603 be applied for secondary outcomes (59).

604 We will also test for baseline cofactors that may influence a stroke survivor's
605 response to the interventions in this study. To do this, we will utilize a multivariate
606 prognostic model that includes comfortable gait speed, lower extremity Fugl-Meyer
607 motor scores, and scores on the Activities-Specific Balance Confidence Scale. These
608 measures were selected based on previous studies suggesting that comfortable gait
609 speed (52, 60-64), lower limb Fugl-Meyer motor scores (64-66), and balance abilities

610 (67) may influence response to gait rehabilitation interventions in individuals with
611 chronic stroke. Other potential cofactors will also be explored to inform future studies.

612 Based on safety data from preliminary studies (33, 53) and extensive previous
613 HIT research among participants with heart disease (24, 68-74) and MAT research
614 among individuals post stroke (15), we expect a similar rate of non-serious adverse
615 events (AEs) between HIT and MAT (e.g. temporary exercise-related soreness and
616 fatigue), without any study-related serious AEs. In the unexpected event of one or more
617 serious adverse events (SAE), the SAE rate will be compared between groups to
618 confirm that there is no significant difference in major safety risk between HIT and MAT.
619 A logistic regression model will be used for this analysis with SAE (yes/no) as the
620 dependent variable and fixed effects for group, site, and baseline gait speed category. If
621 there are SAE(s) in one group only, a continuity correction (0.5 SAEs added to each
622 group) will still allow the odds ratio to be calculated (33).

623

624 **METHODS: MONITORING**

625 ***Data Monitoring:*** The Data and Safety Monitoring Board (DSMB) for this study consists
626 of three independent members separate from the study team at institutions outside of
627 UC, UD and KUMC. Collectively, the DSMB has experience in the management of
628 patients with stroke, exercise, and clinical trials. Persons with a significant conflict of
629 interest were not permitted to be DSMB members. The role of the DSMB is to monitor
630 participant accrual, randomization balance and safety data to assess the risks of study
631 participation.

632 The DSMB meets annually throughout the study, either in person or via
633 teleconference. Additional meetings may be scheduled as requested by the
634 investigators, IRB or DSMB members. The DSMB remains blinded unless it requires the
635 group identities to perform its duties. DSMB meetings include open sessions where the
636 DSMB may discuss any issues with the study team as well as closed sessions where
637 the DSMB alone decides on its recommendations. After each DSMB meeting, the
638 DSMB provides a written report of their discussions and recommendations as to
639 whether the study should continue, whether modifications to the study are needed, or if
640 the study should be terminated. These reports are sent to the investigators, the
641 Institutional Review Board (IRB) and the sponsor. The study may be modified or
642 discontinued at any time by the research team, DSMB, IRB or sponsor to ensure the
643 protection of research participants.

644 **Outcome Data Monitoring.** A blinded co-investigator monitors REDCap
645 outcome data for missing or implausible values.

646 **Study Intervention Fidelity Monitoring.** The site PIs and/or coordinators
647 monitor REDCap intervention data for missing or implausible values and intervention
648 fidelity. Monitored data include the following:

- 649 • **Adherence:** This is measured by the number of training sessions attended and
650 completed.
- 651 • **Aerobic intensity:** This includes the mean and maximum training session HR
652 relative to the target HR range and relative to the previous training sessions. It
653 also includes time spent in target HR zones.

- 654 • **Anaerobic intensity:** This is measured using blood lactate concentration after
655 the treadmill training portion of one session each training week, using a finger
656 stick and a point-of-care blood lactate analyzer.
- 657 • **Neuromotor intensity:** This is measured by treadmill and overground training
658 speeds each session.
- 659 • **Repetition of practice:** This includes step counts during each session,
660 measured by an activity monitor placed on the participant's non-paretic lower
661 extremity.

662 ***Adverse Event and Protocol Deviation Reporting:*** All identified AEs and protocol
663 deviations are reported to the UC IRB and DSMB annually. Unanticipated problems
664 requiring prompt reporting are reported per UC IRB policy (described below). AEs and
665 protocol deviations are reported by study staff to the site PIs on a regular basis and are
666 discussed during study conference calls.

667 We define an AE as 'any unfavorable and unintended sign, symptom, or disease
668 temporally associated with study participation that may or may not be related to study
669 procedures, including any adverse change that occurs at any time following consent
670 and before completing study participation'. An SAE is an AE that results in any of the
671 following outcomes: death, a life-threatening situation, inpatient hospitalization or
672 prolongation of existing hospitalization, or a persistent or significant disability/incapacity.
673 Important medical events that may not result in death, be life-threatening, or require
674 hospitalization may also be considered SAEs when, based on appropriate medical
675 judgment, they may jeopardize the patient and may require medical or surgical
676 intervention to prevent one of the outcomes in this definition.

677 Anticipated AEs are either listed in the study protocol or consent form or have a
678 reasonable likelihood of occurrence in the study population (adults and older adults with
679 stroke). Possible events listed in the protocol or consent form (regardless of likelihood)
680 include discomfort, worry, pain, fatigue, stiffness, skin breakdown, local infection,
681 faintness, nausea, bruising, scarring, fall, injury, myocardial infarction, or other serious
682 heart problems. Events with greater likelihood of occurrence in adults and older adults
683 with stroke include (but are not limited to): pain, fatigue, stiffness, faintness, syncope,
684 vertigo, fall, skin breakdown, bruising, orthopedic injury, recurrent stroke, angina,
685 myocardial infarction, blood clot and seizure.

686 All identified AEs are named using terminology from the Common Terminology
687 Criteria for Adverse Events version 4.03 (CTCAE, National Cancer Institute, 2010);
688 however, “Dizziness” will be categorized as either “Lightheadedness” or “Vertigo”. The
689 CTCAE criteria are also used as a guideline to provide a severity grade for the AE
690 which will range from 1 (mild) to 5 (death). For this study, a serious adverse event is
691 defined as grade $\geq 3/5$ (75).

692 The relationship of an AE to study testing or interventions is determined using
693 pre-defined criteria that considers when the event occurs in relation to testing/training
694 procedures, whether the AE follows a pattern consistent with study procedures, whether
695 it improves when the procedure has stopped or reappears when the procedure is
696 resumed or repeated, and whether an alternative cause or influence may also be
697 present. We also consider the impact of the AE on study interventions. The AE is
698 considered to have no impact on study interventions if study interventions do not require
699 any alteration because of the event. Modification to study interventions would occur

700 when study interventions are modified such that they differ in a substantive way from
701 what is described in the protocol because of the AE. The AE may also result in
702 termination such that the participant withdraws or is withdrawn from the study before
703 completing the intervention because of the AE.

704 Participants are queried about any adverse events at the start and end of each
705 study visit. AEs that are specifically queried include falls, injuries, pain, lightheadedness
706 and fatigue. During study visits, participants are monitored for signs or symptoms of
707 cardiorespiratory insufficiency, new neurologic impairments or orthopedic injury.
708 Whenever a study team member identifies an AE, an Adverse Event Form in REDCap
709 is started and any additional information needed is collected. If the AE is not already
710 resolved when discovered, the study team member follows up on the AE during each
711 visit and/or by phone until it is resolved. The study team member completing the AE
712 form provides a description of the event, its severity, its timing relative to study testing
713 and/or intervention procedures, any possible alternative causes or contributing factors,
714 any AE-related interventions (e.g. pain medicine), any follow up, and if/when the event
715 is resolved. The study team member completing the form also preliminarily grades and
716 categorizes the event using the above guidelines. All AE reports identify participants
717 only by their study ID as these reports are viewed by blinded study team members.
718 Once resolved, AE reports are adjudicated by the blinded study physician to determine
719 the official severity grade and categorization using the information provided by the study
720 team member (the blinded study physician may also request additional information if
721 needed). Withdrawal from the study and modifications to study procedures as a result of

722 an AE or because of therapeutic measures taken to treat an AE are at the discretion of
723 the site PIs, in consultation with the study neurologists or cardiologists as appropriate.

724 A protocol deviation is when one or more procedures described in the study IRB
725 protocol are not followed, either intentionally or unintentionally. Each site maintains a
726 protocol deviation log that is sent to the UC regulatory coordinator upon request. This
727 log includes: 1) a description of the protocol deviation, 2) the date of the deviation, 3)
728 the participant ID(s) affected, 4) whether the protocol deviation was related to
729 screening/enrollment, outcome testing, and/or study intervention, and 5) either a
730 description of the corrective actions taken to prevent recurrence or a rationale of why
731 such actions are not needed.

732 All AEs and protocol deviations are reported by study staff to site PIs on a regular
733 basis and discussed on study conference calls. Any major AEs or protocol deviations
734 are reported to site PIs and the UC PI as soon as possible. All identified AEs and
735 protocol deviations are compiled by UC and reported to the IRB and DSMB annually.
736 The IRB of record for all sites in this study is the University of Cincinnati and requires
737 prompt reporting (within 10 days of discovery) of any unanticipated problems involving
738 risk to participants or others. Events resulting in temporary or permanent interruption of
739 the study activities by a site PI to avoid potential harm to participants are reported to the
740 UC IRB within 48 hours of discovery. The lead site PI reviews the event and determine
741 if it meets criteria for prompt reporting.

742

743

744 **DISCUSSION:**

745 This is the first study designed to compare HIT and MAT post-stroke and the first
746 to compare different HIT durations. Previous work has shown that among healthy
747 adults, HIT delivers significant benefits remarkably faster (within 6 sessions over 2
748 weeks) (76-78), achieving similar improvements to MAT with up to 76% less training
749 time (77, 79-81). If HIT elicits comparable changes among individuals with stroke in 4
750 weeks of training (objective 1 of this study), it would provide a clinically feasible and
751 resource-efficient alternative to the current best-practice model (MAT), which could
752 result in increased exercise engagement among stroke survivors. In addition, no
753 previous studies have compared different HIT durations or examined the time course of
754 outcome changes. This study intends to fill that gap (objective 2) and will provide
755 foundational information to guide dosing of locomotor intensity and duration in future
756 studies and clinical practice.

757 This study is also the first U.S. multi-site trial of post-stroke HIT. Thus, the results
758 of this study will also aid in our understanding of the feasibility of implementing HIT
759 across multiple sites nationally (objective 3). Depending on the results of this research,
760 the next step would be a larger efficacy trial. To that end, this study will provide needed
761 data to design a subsequent definitive trial of the relative efficacy of HIT and MAT for
762 eliciting clinically meaningful and sustained improvements in walking function.

763

764 **Trial Status:** Protocol version 2020-01-21. Recruitment start date: 2019-01-04.

765 Estimated completion date: 2022-02-28.

766 **LIST OF ABBREVIATIONS:**

767 MAT: Moderate-intensity aerobic training; HIT: High-intensity interval training; 10MWT:
768 10-Meter Walk Test; 6MWT: 6-Minute Walk Test; VO₂-peak: peak oxygen uptake; UC:
769 University of Cincinnati; UD: University of Delaware; KUMC: Kansas University Medical
770 Center; MOP: Manual of Operating Procedures; RPE: Rating of Perceived Exertion;
771 GXT: Graded Exercise Test; PRE: pre-blinded outcome testing; 4-WK: 4-week blinded
772 outcome testing; 8-WK: 8-week blinded outcome testing; 12-WK: 12-week blinded
773 outcome testing; LEFM: Lower Extremity Fugl-Meyer; NIHSS: National Institutes of
774 Health Stroke Scale; FAC: Functional Ambulation Category; ABC: Activities Specific
775 Balance Confidence Scale; GROG: Global Rating of Change; ECG: electrocardiogram;
776 PI: Primary Investigator; HR: Heart Rate; HRR: Heart Rate Reserve; MCID: Minimally
777 Clinically Important Difference; DSMB: Data and Safety Monitoring Board; AE: Adverse
778 Event; SAE: Serious Adverse Event; CTCAE: Common Terminology Criteria for
779 Adverse Events

780

781 **DECLARATIONS:**

782 ***Ethics Approval and Consent to Participate:*** This research has been approved by
783 the University of Cincinnati IRB. The University of Cincinnati IRB is the IRB of record for
784 this protocol, and the agreement is managed through SMART IRB. All participants are
785 providing written informed consent prior to participation.

786 ***Consent for Publication:*** Not applicable- this manuscript does not contain an
787 individual person's data.

788 **Availability of Data and Materials:** Data sharing is not applicable to this article as the
789 datasets are currently being generated and have not yet been analyzed. De-identified
790 data will be deposited in the National Institute of Child Health and Human Development
791 (NICHD) Data and Specimen Hub (DASH) repository.

792 **Competing Interests:** The authors declare that they have no competing interests.

793 **Funding:** This study is funded through a grant from the National Institutes of Health:
794 R01HD093694. Funding was also provided to AM from the Foundation for Physical
795 Therapy Research Florence P. Kendall Doctoral Scholarship. These funding sources
796 were not involved in the writing of this manuscript or the decision to submit this protocol
797 for publication.

798 **Authors' Contributions:** AM primary author, primary testing PT at UD. DSR secondary
799 author, UD site PI. SB author, KUMC site PI. KD author, blinded co-investigator. SD
800 author, study coordinator at UC. JW author, KUMC site coordinator. HW author, primary
801 training PT at UD. EW author, primary study coordinator at UC. DC author, co-
802 investigator, blinded centralized assessor of ventilatory thresholds. MG author, co-
803 investigator, study cardiologist. OA author, co-investigator, blinded adverse event
804 adjudicator. JK author, co-investigator, study statistician. BK author, co-investigator,
805 study neurologist. PB senior author, Principal Investigator. All authors read and
806 approved the final manuscript.

807 **Acknowledgements:** Not applicable.

808 **Authors' Information (optional):** Not applicable.

809

810 **References**

- 811 1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart
812 Disease and Stroke Statistics-2016 Update: A Report From the American Heart
813 Association. *Circulation*. 2016;133(4):e38-360.
- 814 2. Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. Guidelines for
815 Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals
816 From the American Heart Association/American Stroke Association. *Stroke*.
817 2016;47(6):e98-e169.
- 818 3. Ada L, Dean CM, Lindley R, Lloyd G. Improving community ambulation after stroke:
819 the AMBULATE Trial. *BMC Neurol*. 2009;9:8.
- 820 4. Hill K, Ellis P, Bernhardt J, Maggs P, Hull S. Balance and mobility outcomes for
821 stroke patients: a comprehensive audit. *Aust J Physiother*. 1997;43(3):173-80.
- 822 5. Jorgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Stoier M, Olsen TS.
823 Outcome and time course of recovery in stroke. Part II: Time course of recovery. The
824 Copenhagen Stroke Study. *Archives of physical medicine and rehabilitation*.
825 1995;76(5):406-12.
- 826 6. Mayo NE, Wood-Dauphinee S, Cote R, Durcan L, Carlton J. Activity, participation,
827 and quality of life 6 months poststroke. *Archives of physical medicine and rehabilitation*.
828 2002;83(8):1035-42.
- 829 7. Bohannon RW, Horton MG, Wikholm JB. Importance of four variables of walking to
830 patients with stroke. *Int J Rehabil Res*. 1991;14(3):246-50.
- 831 8. Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, et al. Physical
832 activity and exercise recommendations for stroke survivors: a statement for healthcare
833 professionals from the American Heart Association/American Stroke Association.
834 *Stroke*. 2014;45(8):2532-53.
- 835 9. Marsden DL, Dunn A, Callister R, Levi CR, Spratt NJ. Characteristics of exercise
836 training interventions to improve cardiorespiratory fitness after stroke: a systematic
837 review with meta-analysis. *Neurorehabil Neural Repair*. 2013;27(9):775-88.
- 838 10. Pang MY, Charlesworth SA, Lau RW, Chung RC. Using aerobic exercise to improve
839 health outcomes and quality of life in stroke: evidence-based exercise prescription
840 recommendations. *Cerebrovasc Dis*. 2013;35(1):7-22.
- 841 11. Stoller O, de Bruin ED, Knols RH, Hunt KJ. Effects of cardiovascular exercise early
842 after stroke: systematic review and meta-analysis. *BMC Neurol*. 2012;12:45.
- 843 12. Kendall BJ, Gothe NP. Effect of Aerobic Exercise Interventions on Mobility among
844 Stroke Patients: A Systematic Review. *American journal of physical medicine &*
845 *rehabilitation*. 2016;95(3):214-24.
- 846 13. Mehta S, Pereira S, Janzen S, Mays R, Viana R, Lobo L, et al. Cardiovascular
847 conditioning for comfortable gait speed and total distance walked during the chronic
848 stage of stroke: a meta-analysis. *Topics in stroke rehabilitation*. 2012;19(6):463-70.

- 849 14. Saunders DH, Sanderson M, Brazzelli M, Greig CA, Mead GE. Physical fitness
850 training for stroke patients. *Cochrane Database Syst Rev.* 2013(10):Cd003316.
- 851 15. Ivey FM, Hafer-Macko CE, Macko RF. Task-oriented treadmill exercise training in
852 chronic hemiparetic stroke. *J Rehabil Res Dev.* 2008;45(2):249-59.
- 853 16. Ivey FM, Hafer-Macko CE, Ryan AS, Macko RF. Impaired leg vasodilatory function
854 after stroke: adaptations with treadmill exercise training. *Stroke.* 2010;41(12):2913-7.
- 855 17. Ivey FM, Ryan AS, Hafer-Macko CE, Goldberg AP, Macko RF. Treadmill aerobic
856 training improves glucose tolerance and indices of insulin sensitivity in disabled stroke
857 survivors: a preliminary report. *Stroke.* 2007;38(10):2752-8.
- 858 18. Ivey FM, Ryan AS, Hafer-Macko CE, Macko RF. Improved cerebral vasomotor
859 reactivity after exercise training in hemiparetic stroke survivors. *Stroke.*
860 2011;42(7):1994-2000.
- 861 19. Luft AR, Macko RF, Forrester LW, Villagra F, Ivey F, Sorkin JD, et al. Treadmill
862 exercise activates subcortical neural networks and improves walking after stroke: a
863 randomized controlled trial. *Stroke.* 2008;39(12):3341-50.
- 864 20. Macko RF, DeSouza CA, Tretter LD, Silver KH, Smith GV, Anderson PA, et al.
865 Treadmill aerobic exercise training reduces the energy expenditure and cardiovascular
866 demands of hemiparetic gait in chronic stroke patients. A preliminary report. *Stroke.*
867 1997;28(2):326-30.
- 868 21. Macko RF, Ivey FM, Forrester LW, Hanley D, Sorkin JD, Katzell LI, et al. Treadmill
869 exercise rehabilitation improves ambulatory function and cardiovascular fitness in
870 patients with chronic stroke: a randomized, controlled trial. *Stroke.* 2005;36(10):2206-
871 11.
- 872 22. Macko RF, Smith GV, Dobrovoly CL, Sorkin JD, Goldberg AP, Silver KH. Treadmill
873 training improves fitness reserve in chronic stroke patients. *Archives of physical
874 medicine and rehabilitation.* 2001;82(7):879-84.
- 875 23. Jurkiewicz MT, Marzolini S, Oh P. Adherence to a home-based exercise program for
876 individuals after stroke. *Topics in stroke rehabilitation.* 2011;18(3):277-84.
- 877 24. Moholdt T, Aamot IL, Granoien I, Gjerde L, Myklebust G, Walderhaug L, et al. Long-
878 term follow-up after cardiac rehabilitation: a randomized study of usual care exercise
879 training versus aerobic interval training after myocardial infarction. *Int J Cardiol.*
880 2011;152(3):388-90.
- 881 25. Tiedemann A, Sherrington C, Dean CM, Rissel C, Lord SR, Kirkham C, et al.
882 Predictors of adherence to a structured exercise program and physical activity
883 participation in community dwellers after stroke. *Stroke Res Treat.* 2012;2012:136525.
- 884 26. Duncan P, Studenski S, Richards L, Gollub S, Lai SM, Reker D, et al. Randomized
885 clinical trial of therapeutic exercise in subacute stroke. *Stroke.* 2003;34(9):2173-80.
- 886 27. Kwakkel G. Impact of intensity of practice after stroke: issues for consideration.
887 *Disability and rehabilitation.* 2006;28(13-14):823-30.

- 888 28. Boyne P, Dunning K, Carl D, Gerson M, Khoury J, Kissela B. High-intensity interval
889 training in stroke rehabilitation. *Topics in stroke rehabilitation*. 2013;20(4):317-30.
- 890 29. Billinger SA, Boyne P, Coughenour E, Dunning K, Mattlage A. Does aerobic
891 exercise and the FITT principle fit into stroke recovery? *Curr Neurol Neurosci Rep*.
892 2015;15(2):519.
- 893 30. Boyne P, Billinger S, MacKay-Lyons M, Barney B, Khoury J, Dunning K. Aerobic
894 Exercise Prescription in Stroke Rehabilitation: A Web-Based Survey of US Physical
895 Therapists. *J Neurol Phys Ther*. 2017;41(2):119-28.
- 896 31. Lau KW, Mak MK. Speed-dependent treadmill training is effective to improve gait
897 and balance performance in patients with sub-acute stroke. *J Rehabil Med*.
898 2011;43(8):709-13.
- 899 32. Pohl M, Mehrholz J, Ritschel C, Rückriem S. Speed-dependent treadmill training in
900 ambulatory hemiparetic stroke patients: a randomized controlled trial. *Stroke*.
901 2002;33(2):553-8.
- 902 33. Boyne P, Dunning K, Carl D, Gerson M, Khoury J, Rockwell B, et al. High-Intensity
903 Interval Training and Moderate-Intensity Continuous Training in Ambulatory Chronic
904 Stroke: Feasibility Study. *Physical therapy*. 2016;96(10):1533-44.
- 905 34. Boyne P, Scholl V, Doren S, Carl D, Billinger SA, Reisman DS, et al. Locomotor
906 training intensity after stroke: Effects of interval type and mode. *Topics in stroke*
907 *rehabilitation*. 2020:1-11.
- 908 35. Reisman D, Kesar T, Perumal R, Roos M, Rudolph K, Higginson J, et al. Time
909 course of functional and biomechanical improvements during a gait training intervention
910 in persons with chronic stroke. *J Neurol Phys Ther*. 2013;37(4):159-65.
- 911 36. Williams LS, Brizendine EJ, Plue L, Bakas T, Tu W, Hendrie H, et al. Performance
912 of the PHQ-9 as a screening tool for depression after stroke. *Stroke*. 2005;36(3):635-8.
- 913 37. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke
914 hemiplegic patient. 1. a method for evaluation of physical performance. *Scand J Rehabil*
915 *Med*. 1975;7(1):13-31.
- 916 38. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of
917 muscle spasticity. *Physical therapy*. 1987;67(2):206-7.
- 918 39. Brott T, Adams HP, Jr., Olinger CP, Marler JR, Barsan WG, Biller J, et al.
919 Measurements of acute cerebral infarction: a clinical examination scale. *Stroke*.
920 1989;20(7):864-70.
- 921 40. Flansbjer UB, Holmback AM, Downham D, Patten C, Lexell J. Reliability of gait
922 performance tests in men and women with hemiparesis after stroke. *J Rehabil Med*.
923 2005;37(2):75-82.
- 924 41. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*.
925 2002;166(1):111-7.

- 926 42. Eng JJ, Dawson AS, Chu KS. Submaximal exercise in persons with stroke: test-
927 retest reliability and concurrent validity with maximal oxygen consumption. *Archives of*
928 *physical medicine and rehabilitation*. 2004;85(1):113-8.
- 929 43. Borg G. Perceived exertion as an indicator of somatic stress. *Scand J Rehabil Med*.
930 1970;2(2):92-8.
- 931 44. Pescatello LS, American College of Sports M. ACSM's guidelines for exercise
932 testing and prescription. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins
933 Health; 2014.
- 934 45. Boyne P, Reisman D, Brian M, Barney B, Franke A, Carl D, et al. Ventilatory
935 threshold may be a more specific measure of aerobic capacity than peak oxygen
936 consumption rate in persons with stroke. *Topics in stroke rehabilitation*. 2017;24(2):149-
937 57.
- 938 46. Tucker CA, Escorpizo R, Cieza A, Lai JS, Stucki G, Ustun TB, et al. Mapping the
939 content of the Patient-Reported Outcomes Measurement Information System
940 (PROMIS(R)) using the International Classification of Functioning, Health and Disability.
941 *Qual Life Res*. 2014;23(9):2431-8.
- 942 47. Mehrholz J, Wagner K, Rutte K, Meissner D, Pohl M. Predictive validity and
943 responsiveness of the functional ambulation category in hemiparetic patients after
944 stroke. *Archives of physical medicine and rehabilitation*. 2007;88(10):1314-9.
- 945 48. Golicki D, Niewada M, Buczek J, Karlinska A, Kobayashi A, Janssen MF, et al.
946 Validity of EQ-5D-5L in stroke. *Qual Life Res*. 2015;24(4):845-50.
- 947 49. Salbach NM, Mayo NE, Hanley JA, Richards CL, Wood-Dauphinee S. Psychometric
948 evaluation of the original and Canadian French version of the activities-specific balance
949 confidence scale among people with stroke. *Archives of physical medicine and*
950 *rehabilitation*. 2006;87(12):1597-604.
- 951 50. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the
952 minimal clinically important difference. *Control Clin Trials*. 1989;10(4):407-15.
- 953 51. Ada L, Dean CM, Lindley R. Randomized trial of treadmill training to improve
954 walking in community-dwelling people after stroke: the AMBULATE trial. *Int J Stroke*.
955 2013;8(6):436-44.
- 956 52. Dean CM, Ada L, Lindley RI. Treadmill training provides greater benefit to the
957 subgroup of community-dwelling people after stroke who walk faster than 0.4m/s: a
958 randomised trial. *J Physiother*. 2014;60(2):97-101.
- 959 53. Boyne P, Dunning K, Carl D, Gerson M, Khoury J, Kissela B. Within-session
960 responses to high-intensity interval training in chronic stroke. *Medicine and science in*
961 *sports and exercise*. 2015;47(3):476-84.
- 962 54. Boyne P, Meyrose C, Westover J, Whitesel D, Hatter K, Reisman DS, et al. Effects
963 of Exercise Intensity on Acute Circulating Molecular Responses Poststroke.
964 *Neurorehabil Neural Repair*. 2020;34(3):222-34.

- 965 55. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and
966 responsiveness in common physical performance measures in older adults. *J Am*
967 *Geriatr Soc.* 2006;54(5):743-9.
- 968 56. Guo Y, Logan HL, Glueck DH, Muller KE. Selecting a sample size for studies with
969 repeated measures. *BMC Med Res Methodol.* 2013;13:100.
- 970 57. Fitzmaurice G, Laird N, Ware J. *Applied longitudinal analysis.* 2nd ed. Hoboken, NJ:
971 John Wiley & Sons, Inc.; 2011.
- 972 58. Dobkin BH. Progressive Staging of Pilot Studies to Improve Phase III Trials for
973 Motor Interventions. *Neurorehabil Neural Repair.* 2009;23(3):197-206.
- 974 59. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
975 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B*
976 *(Methodological).* 1995;57(1):289-300.
- 977 60. Dean CM, Rissel C, Sherrington C, Sharkey M, Cumming RG, Lord SR, et al.
978 Exercise to enhance mobility and prevent falls after stroke: the community stroke club
979 randomized trial. *Neurorehabil Neural Repair.* 2012;26(9):1046-57.
- 980 61. Hornby TG, Campbell DD, Kahn JH, Demott T, Moore JL, Roth HR. Enhanced gait-
981 related improvements after therapist- versus robotic-assisted locomotor training in
982 subjects with chronic stroke: a randomized controlled study. *Stroke.* 2008;39(6):1786-
983 92.
- 984 62. Kim DK, Oh DW. Repeated Use of 6-min Walk Test with Immediate Knowledge of
985 Results for Walking Capacity in Chronic Stroke: Clinical Trial of Fast versus Slow
986 Walkers. *Journal of stroke and cerebrovascular diseases : the official journal of National*
987 *Stroke Association.* 2019;28(11):104337.
- 988 63. Salbach NM, Mayo NE, Wood-Dauphinee S, Hanley JA, Richards CL, Côté R. A
989 task-orientated intervention enhances walking distance and speed in the first year post
990 stroke: a randomized controlled trial. *Clin Rehabil.* 2004;18(5):509-19.
- 991 64. Sullivan KJ, Knowlton BJ, Dobkin BH. Step training with body weight support: effect
992 of treadmill speed and practice paradigms on poststroke locomotor recovery. *Archives*
993 *of physical medicine and rehabilitation.* 2002;83(5):683-91.
- 994 65. Bowden MG, Behrman AL, Neptune RR, Gregory CM, Kautz SA. Locomotor
995 rehabilitation of individuals with chronic stroke: difference between responders and
996 nonresponders. *Archives of physical medicine and rehabilitation.* 2013;94(5):856-62.
- 997 66. Burke E, Dobkin BH, Noser EA, Enney LA, Cramer SC. Predictors and biomarkers
998 of treatment gains in a clinical stroke trial targeting the lower extremity. *Stroke.*
999 2014;45(8):2379-84.
- 1000 67. Dobkin BH, Nadeau SE, Behrman AL, Wu SS, Rose DK, Bowden M, et al.
1001 Prediction of responders for outcome measures of locomotor Experience Applied Post
1002 Stroke trial. *J Rehabil Res Dev.* 2014;51(1):39-50.
- 1003 68. Freyssin C, Verkindt C, Prieur F, Benaich P, Maunier S, Blanc P. Cardiac
1004 rehabilitation in chronic heart failure: effect of an 8-week, high-intensity interval training

- 1005 versus continuous training. Archives of physical medicine and rehabilitation.
1006 2012;93(8):1359-64.
- 1007 69. Fu TC, Wang CH, Lin PS, Hsu CC, Cherng WJ, Huang SC, et al. Aerobic interval
1008 training improves oxygen uptake efficiency by enhancing cerebral and muscular
1009 hemodynamics in patients with heart failure. *Int J Cardiol.* 2013;167(1):41-50.
- 1010 70. Guiraud T, Nigam A, Gremeaux V, Meyer P, Juneau M, Bosquet L. High-intensity
1011 interval training in cardiac rehabilitation. *Sports Med.* 2012;42(7):587-605.
- 1012 71. Moholdt T, Aamot IL, Granoien I, Gjerde L, Myklebust G, Walderhaug L, et al.
1013 Aerobic interval training increases peak oxygen uptake more than usual care exercise
1014 training in myocardial infarction patients: a randomized controlled study. *Clin Rehabil.*
1015 2012;26(1):33-44.
- 1016 72. Moholdt TT, Amundsen BH, Rustad LA, Wahba A, Lovo KT, Gullikstad LR, et al.
1017 Aerobic interval training versus continuous moderate exercise after coronary artery
1018 bypass surgery: a randomized study of cardiovascular effects and quality of life. *Am*
1019 *Heart J.* 2009;158(6):1031-7.
- 1020 73. Rognmo O, Hetland E, Helgerud J, Hoff J, Slordahl SA. High intensity aerobic
1021 interval exercise is superior to moderate intensity exercise for increasing aerobic
1022 capacity in patients with coronary artery disease. *Eur J Cardiovasc Prev Rehabil.*
1023 2004;11(3):216-22.
- 1024 74. Wisloff U, Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram PM, et al.
1025 Superior cardiovascular effect of aerobic interval training versus moderate continuous
1026 training in heart failure patients: a randomized study. *Circulation.* 2007;115(24):3086-94.
- 1027 75. Common terminology criteria for adverse events (CTCAE) version 4.0. National
1028 Cancer Institute. 2009.
- 1029 76. Burgomaster KA, Hughes SC, Heigenhauser GJ, Bradwell SN, Gibala MJ. Six
1030 sessions of sprint interval training increases muscle oxidative potential and cycle
1031 endurance capacity in humans. *J Appl Physiol (1985).* 2005;98(6):1985-90.
- 1032 77. Gibala MJ, Little JP, van Essen M, Wilkin GP, Burgomaster KA, Safdar A, et al.
1033 Short-term sprint interval versus traditional endurance training: similar initial adaptations
1034 in human skeletal muscle and exercise performance. *J Physiol.* 2006;575(Pt 3):901-11.
- 1035 78. Hood MS, Little JP, Tarnopolsky MA, Myslik F, Gibala MJ. Low-volume interval
1036 training improves muscle oxidative capacity in sedentary adults. *Medicine and science*
1037 *in sports and exercise.* 2011;43(10):1849-56.
- 1038 79. Bartlett JD, Hwa Joo C, Jeong TS, Louhelainen J, Cochran AJ, Gibala MJ, et al.
1039 Matched work high-intensity interval and continuous running induce similar increases in
1040 PGC-1 α mRNA, AMPK, p38, and p53 phosphorylation in human skeletal muscle. *J*
1041 *Appl Physiol (1985).* 2012;112(7):1135-43.
- 1042 80. Burgomaster KA, Howarth KR, Phillips SM, Rakobowchuk M, Macdonald MJ,
1043 McGee SL, et al. Similar metabolic adaptations during exercise after low volume sprint
1044 interval and traditional endurance training in humans. *J Physiol.* 2008;586(1):151-60.

1045 81. Rakobowchuk M, Tanguay S, Burgomaster KA, Howarth KR, Gibala MJ, MacDonald
1046 MJ. Sprint interval and traditional endurance training induce similar improvements in
1047 peripheral arterial stiffness and flow-mediated dilation in healthy humans. *Am J Physiol*
1048 *Regul Integr Comp Physiol*. 2008;295(1):R236-42.

1049

1050

1051


1052

1053

1054 **Figure 1.** Study Schedule and Participant Flow Diagram

1055 HIT- high-intensity interval training, MAT- moderate-intensity aerobic training

1056



1057